In conclusion , NVBBs , but not VBBs , determine a lower reduction in cSBP than in pSBP .
However , the difference in treatment-induced SBP amplification changes between NVBB and VBB is nearly abolished after accounting for differences in heart rate changes
β-Blockers are less effective than other antihypertensive drug classes in reducing central systolic blood pressure ( cSBP ) as compared with peripheral SBP ( pSBP ) .
Whether this effect is less pronounced with vasodilating β-blockers ( VBB ) when compared with nonvasodilating β-blockers ( NVBB ) remains unsettled .
Central hemodynamics in prehypertension: effect of the β-adrenergic antagonist nebivolol.
The aim of the current study was to characterize the effects of the novel β-adrenergic antagonist nebivolol on central aortic blood pressures , arterial properties , and nitroxidergic activity in individuals with prehypertension . Prehypertension is emerging as a major risk factor for several adverse cardiovascular consequences . Increased pulse wave velocity , aortic augmentation index , and aortic blood pressures have been linked with augmented risk of cardiovascular disease and mortality . While the effects of antihypertensive drugs on these parameters in hypertensive patients have been studied , there are limited data so far in prehypertension . Fifty individuals with prehypertension were r and omized to either nebivolol ( 5 mg per day ) or placebo in a double-blind clinical trial . Patients underwent measurement of pulse wave velocity as well as aortic blood pressure and aortic augmentation index via pulse wave analysis at baseline and 8 weeks . Patients also had blood and urine biochemistries done at each visit . Nebivolol achieved significant reductions in central aortic systolic ( P=.011 ) , diastolic ( P=.009 ) , and mean arterial blood pressure ( P=.002 ) . Pulse wave velocity trended toward improvement but did not achieve significance ( P=.088 ) . Nitric oxide production , measured as urinary nitrite/nitrite excretion , also rose substantially in the nebivolol group ( by approximately 60 % , P=.030 ) . Central blood pressures can be effectively lowered by β-blockade while patients are still in the prehypertension phase , and the effects may be coupled to improve nitric oxide release by the drug
In conclusion , NVBBs , but not VBBs , determine a lower reduction in cSBP than in pSBP .
However , the difference in treatment-induced SBP amplification changes between NVBB and VBB is nearly abolished after accounting for differences in heart rate changes
β-Blockers are less effective than other antihypertensive drug classes in reducing central systolic blood pressure ( cSBP ) as compared with peripheral SBP ( pSBP ) .
Whether this effect is less pronounced with vasodilating β-blockers ( VBB ) when compared with nonvasodilating β-blockers ( NVBB ) remains unsettled .